{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:24:37Z","timestamp":1787318677342,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is the leading cause of dementia worldwide, and cost-effective tools to detect amyloid pathology are urgently needed. Blood-based Tau phosphorylated at threonine 217 (pTau217) seems promising, but its reliability as a proxy for cerebrospinal fluid (CSF) status and ability to identify patients within the AD spectrum remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic\u00a0review and meta-analysis on the potential of blood pTau217 to differentiate amyloid-positive (A+) and amyloid-negative (A\u2212) subjects. We included original studies reporting quantitative data on pTau217 concentrations in both blood and CSF in the AD continuum. The single-group meta-analysis computed the pooled pTau217 levels in blood and in CSF, separately in the A+ and A\u2212 groups, while the head-to-head meta-analysis compared the mean pTau217 concentrations in the A+ versus A\u2212 subjects, both in blood and CSF, stratifying by assessment method in both cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies (819 A+; 1055 A\u2212) were included. The mean pTau217 levels resulted higher in CSF than in blood and, crucially, in A+ individuals than in A\u2013 ones, regardless of the laboratory method employed. Most importantly, all laboratory techniques reliably distinguished A+ from A\u2013 subjects, whether applied to CSF or blood samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results confirm that blood-based pTau217 is a reliable marker of amyloid pathology with significant implications for clinical practice in the AD continuum. Indeed, pTau217 might be a non-invasive, scalable biomarker for early AD detection, reducing the reliance on more invasive, expansive, and less accessible methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Prospero CRD42024565187<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-12996-3","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:52:45Z","timestamp":1741247565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-6418","authenticated-orcid":false,"given":"Annibale","family":"Antonioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Maria","family":"Raho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Manzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Flacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"12996_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) Alzheimer\u2019s Disease: Epidemiology and Clinical Progression. Neurol Ther 11:553\u2013569. https:\/\/doi.org\/10.1007\/s40120-022-00338-8","journal-title":"Neurol Ther"},{"key":"12996_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assun\u00e7\u00e3o","year":"2022","unstructured":"Assun\u00e7\u00e3o SS, Sperling RA, Ritchie C et al (2022) Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimers Res Ther 14:54. https:\/\/doi.org\/10.1186\/s13195-022-00984-y","journal-title":"Alzheimers Res Ther"},{"key":"12996_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DNND.S228939","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H (2019) Alzheimer\u2019s Disease - Why We Need Early Diagnosis. Degener Neurol Neuromuscul Dis 9:123\u2013130. https:\/\/doi.org\/10.2147\/DNND.S228939","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"12996_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM (2023) Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med 29:2187\u20132199. https:\/\/doi.org\/10.1038\/s41591-023-02505-2","journal-title":"Nat Med"},{"key":"12996_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"12996_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging 3:506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3","journal-title":"Nat Aging"},{"key":"12996_CR7","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G et al (2022) The blood-brain barrier in aging and neurodegeneration. Mol Psychiatr 27:2659\u20132673. https:\/\/doi.org\/10.1038\/s41380-022-01511-z","journal-title":"Mol Psychiatr"},{"key":"12996_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL et al (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554:249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"key":"12996_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG et al (2022) The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimer\u2019s Res Ther 14:195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"12996_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07258-x","author":"A Antonioni","year":"2023","unstructured":"Antonioni A, Raho EM, Di Lorenzo F (2023) Is blood pTau a reliable indicator of the CSF status? A narrative review. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-023-07258-x","journal-title":"Neurol Sci"},{"key":"12996_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15:673\u2013684. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"key":"12996_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neubiorev.2021.07.007","volume":"128","author":"Y Qu","year":"2021","unstructured":"Qu Y, Ma Y-H, Huang Y-Y et al (2021) Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and meta-analysis. Neurosci Biobehav Rev 128:479\u2013486. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.07.007","journal-title":"Neurosci Biobehav Rev"},{"key":"12996_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/joim.13332","volume":"290","author":"DOT Alawode","year":"2021","unstructured":"Alawode DOT, Heslegrave AJ, Ashton NJ et al (2021) Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer\u2019s disease. J Intern Med 290:583\u2013601. https:\/\/doi.org\/10.1111\/joim.13332","journal-title":"J Intern Med"},{"key":"12996_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G et al (2024) Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol 81:255\u2013263. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"key":"12996_CR15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146:1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"key":"12996_CR16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M et al (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med 28:1797\u20131801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w","journal-title":"Nat Med"},{"key":"12996_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","volume":"22","author":"CRS Belder","year":"2023","unstructured":"Belder CRS, Schott JM, Fox NC (2023) Preparing for disease-modifying therapies in Alzheimer\u2019s disease. Lancet Neurol 22:782\u2013783. https:\/\/doi.org\/10.1016\/S1474-4422(23)00274-0","journal-title":"Lancet Neurol"},{"key":"12996_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.14283\/jpad.2024.83","volume":"11","author":"R Korologou-Linden","year":"2024","unstructured":"Korologou-Linden R, Kalsi J, Kafetsouli D et al (2024) Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer\u2019s Disease. Are We Ready for the New Era? J Prev Alzheimers Dis 11:897\u2013902. https:\/\/doi.org\/10.14283\/jpad.2024.83","journal-title":"J Prev Alzheimers Dis"},{"key":"12996_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"12996_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"12996_CR21","unstructured":"Higgins JPT, Green, S. (2011) Cochrane Handbook for Systematic Reviews of Interventions. In: The Cochrane Collaboration. Available from: www.cochrane-handbook.org."},{"key":"12996_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M et al (2023) Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19:1913\u20131924. https:\/\/doi.org\/10.1002\/alz.12841","journal-title":"Alzheimers Dement"},{"key":"12996_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-024-01391-1","volume":"16","author":"D Bali","year":"2024","unstructured":"Bali D, Hansson O, Janelidze S (2024) Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Alzheimer\u2019s Res Ther 16:31. https:\/\/doi.org\/10.1186\/s13195-024-01391-1","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"12996_CR24","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 217:e20200861. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"key":"12996_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01005-8","author":"C Groot","year":"2022","unstructured":"Groot C, Cicognola C, Bali D et al (2022) Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer\u2019s Res Ther. https:\/\/doi.org\/10.1186\/s13195-022-01005-8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"12996_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E et al (2024) Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol 81:69\u201378. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4596","journal-title":"JAMA Neurol"},{"key":"12996_CR27","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A et al (2024) Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol 271:2053\u20132066. https:\/\/doi.org\/10.1007\/s00415-023-12148-5","journal-title":"J Neurol"},{"key":"12996_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13195-024-01503-x","volume":"16","author":"A Ordu\u00f1a Dolado","year":"2024","unstructured":"Ordu\u00f1a Dolado A, Stomrud E, Ashton NJ et al (2024) Effects of time of the day at sampling on CSF and plasma levels of Alzheimer\u2019 disease biomarkers. Alzheimers Res Ther 16:132. https:\/\/doi.org\/10.1186\/s13195-024-01503-x","journal-title":"Alzheimers Res Ther"},{"key":"12996_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E et al (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.201911170","journal-title":"EMBO Mol Med"},{"key":"12996_CR30","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I et al (2024) Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine 102:105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046","journal-title":"EBioMedicine"},{"key":"12996_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C et al (2023) Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13026","journal-title":"Alzheimers Dement"},{"key":"12996_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC et al (2021) Alzheimer disease. Nat Rev Dis Primers 7:1\u201321. https:\/\/doi.org\/10.1038\/s41572-021-00269-y","journal-title":"Nat Rev Dis Primers"},{"key":"12996_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396:413\u2013446. https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6","journal-title":"Lancet"},{"key":"12996_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH et al (2016) Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002","journal-title":"Alzheimers Dement"},{"key":"12996_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JAD-220046","volume":"87","author":"E Lacorte","year":"2022","unstructured":"Lacorte E, Ancidoni A, Zaccaria V et al (2022) Safety and Efficacy of Monoclonal Antibodies for Alzheimer\u2019s Disease A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. J Alzheimer\u2019s Dis 87:101\u2013129. https:\/\/doi.org\/10.3233\/JAD-220046","journal-title":"J Alzheimer\u2019s Dis"},{"key":"12996_CR36","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1212\/CON.0000000000001504","volume":"30","author":"D Jones","year":"2024","unstructured":"Jones D, Pelak V, Rogalski E (2024) Atypical Presentations of Alzheimer Disease. Continuum (Minneap Minn) 30:1614\u20131641. https:\/\/doi.org\/10.1212\/CON.0000000000001504","journal-title":"Continuum (Minneap Minn)"},{"key":"12996_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/fampra\/cmn071","volume":"25","author":"O Kostopoulou","year":"2008","unstructured":"Kostopoulou O, Delaney BC, Munro CW (2008) Diagnostic difficulty and error in primary care\u2013a systematic review. Fam Pract 25:400\u2013413. https:\/\/doi.org\/10.1093\/fampra\/cmn071","journal-title":"Fam Pract"},{"key":"12996_CR38","doi-asserted-by":"publisher","first-page":"E975","DOI":"10.1212\/WNL.0000000000011416","volume":"96","author":"J Therriault","year":"2021","unstructured":"Therriault J, Pascoal TA, Benedet AL et al (2021) Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon 4, and Cognitive Impairment. Neurology 96:E975\u2013E985. https:\/\/doi.org\/10.1212\/WNL.0000000000011416","journal-title":"Neurology"},{"key":"12996_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG et al (2021) Aducanumab Appropriate Use Recommendations. J Prev Alzheimers Dis 8:398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41","journal-title":"J Prev Alzheimers Dis"},{"key":"12996_CR40","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dementia 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimer\u2019s Dementia"},{"key":"12996_CR41","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med 384:1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"12996_CR42","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"12996_CR43","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.3390\/ijms241411732","volume":"24","author":"A Antonioni","year":"2023","unstructured":"Antonioni A, Raho EM, Lopriore P et al (2023) Frontotemporal Dementia, Where Do We Stand? A Narrative Review. IJMS 24:11732. https:\/\/doi.org\/10.3390\/ijms241411732","journal-title":"IJMS"},{"key":"12996_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S et al (2023) Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol 80:188\u2013199. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","journal-title":"JAMA Neurol"},{"key":"12996_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"12996_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S et al (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging 1:114\u2013123. https:\/\/doi.org\/10.1038\/s43587-020-00003-5","journal-title":"Nature Aging"},{"key":"12996_CR47","doi-asserted-by":"publisher","first-page":"e70068","DOI":"10.1002\/dad2.70068","volume":"17","author":"A Antonioni","year":"2025","unstructured":"Antonioni A, Raho EM, Manzoli L et al (2025) Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer\u2019s disease continuum: A systematic review and meta-analysis. Alzheimer\u2019s Dementia: Diagnos, Assess Dis Monit 17:e70068. https:\/\/doi.org\/10.1002\/dad2.70068","journal-title":"Alzheimer\u2019s Dementia: Diagnos, Assess Dis Monit"},{"key":"12996_CR48","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL et al (2021) Comparison of Plasma Phosphorylated Tau Species with Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol 78:1108\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293","journal-title":"JAMA Neurol"},{"key":"12996_CR49","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - J Am Med Assoc 324:772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA - J Am Med Assoc"},{"key":"12996_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A et al (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20:739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"key":"12996_CR51","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ et al (2023) Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med 15:e17123. https:\/\/doi.org\/10.15252\/emmm.202217123","journal-title":"EMBO Mol Med"},{"key":"12996_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00939-9","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B et al (2021) Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer\u2019s Res Ther. https:\/\/doi.org\/10.1186\/s13195-021-00939-9","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"12996_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS et al (2023) Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegen 18:18. https:\/\/doi.org\/10.1186\/s13024-023-00605-8","journal-title":"Mol Neurodegen"},{"key":"12996_CR54","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD et al (2022) Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28:1398\u20131405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2","journal-title":"Nat Med"},{"key":"12996_CR55","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(02)07948-5","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes DA, Schulz KF (2002) Uses and abuses of screening tests. Lancet 359:881\u2013884. https:\/\/doi.org\/10.1016\/S0140-6736(02)07948-5","journal-title":"Lancet"},{"key":"12996_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 3:1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5","journal-title":"Nat Aging"},{"key":"12996_CR57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC et al (2022) Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease. JAMA Neurol 79:1250\u20131259. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392","journal-title":"JAMA Neurol"},{"key":"12996_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/jnen\/nlaa014","volume":"79","author":"K Gauthreaux","year":"2020","unstructured":"Gauthreaux K, Bonnett TA, Besser LM et al (2020) Concordance of clinical alzheimer diagnosis and neuropathological features at autopsy. J Neuropathol Exp Neurol 79:465\u2013473. https:\/\/doi.org\/10.1093\/jnen\/nlaa014","journal-title":"J Neuropathol Exp Neurol"},{"key":"12996_CR59","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC et al (2024) Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol 20:426\u2013439. https:\/\/doi.org\/10.1038\/s41582-024-00977-5","journal-title":"Nat Rev Neurol"},{"key":"12996_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/JAD-215098","volume":"86","author":"RJ Jutten","year":"2022","unstructured":"Jutten RJ, Thompson L, Sikkes SAM et al (2022) A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer\u2019s Disease: Towards a More Continuous Approach. J Alzheimer\u2019s Dis 86:511\u2013524. https:\/\/doi.org\/10.3233\/JAD-215098","journal-title":"J Alzheimer\u2019s Dis"},{"key":"12996_CR61","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL et al (2022) The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 18:2669\u20132686. https:\/\/doi.org\/10.1002\/alz.12756","journal-title":"Alzheimers Dement"},{"key":"12996_CR62","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 18:400\u2013418. https:\/\/doi.org\/10.1038\/s41582-022-00665-2","journal-title":"Nat Rev Neurol"},{"key":"12996_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00018-015-2050-8","volume":"73","author":"MMA Almutairi","year":"2016","unstructured":"Almutairi MMA, Gong C, Xu YG et al (2016) Factors controlling permeability of the blood\u2013brain barrier. Cell Mol Life Sci 73:57\u201377. https:\/\/doi.org\/10.1007\/s00018-015-2050-8","journal-title":"Cell Mol Life Sci"},{"key":"12996_CR64","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.26134","volume":"90","author":"Z Lin","year":"2021","unstructured":"Lin Z, Sur S, Liu P et al (2021) Blood-Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease. Ann Neurol 90:227\u2013238. https:\/\/doi.org\/10.1002\/ana.26134","journal-title":"Ann Neurol"},{"key":"12996_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-33330-0_4","volume-title":"Frailty and Cardiovascular Diseases : Research into an Elderly Population","author":"M Noale","year":"2020","unstructured":"Noale M, Limongi F, Maggi S (2020) Epidemiology of Cardiovascular Diseases in the Elderly. In: Veronese N (ed) Frailty and Cardiovascular Diseases\u202f: Research into an Elderly Population. Springer International Publishing, Cham, pp 29\u201338"},{"key":"12996_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13014","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Puig-Pijoan A, Ferrari-Souza JP et al (2023) Blood-brain barrier integrity impacts the use of plasma amyloid-\u03b2 as a proxy of brain amyloid-\u03b2 pathology. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13014","journal-title":"Alzheimers Dement"},{"key":"12996_CR67","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 30:1085\u20131095. https:\/\/doi.org\/10.1038\/s41591-024-02869-z","journal-title":"Nat Med"},{"key":"12996_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-230799","volume":"98","author":"Z Li","year":"2024","unstructured":"Li Z, Fan Z, Zhang Q (2024) The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis. J Alzheimer\u2019s Dis 98:13\u201332. https:\/\/doi.org\/10.3233\/JAD-230799","journal-title":"J Alzheimer\u2019s Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12996-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:40:30Z","timestamp":1742218830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12996-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12996"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12996-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all the authors, the corresponding authors state that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"252"}}